23andMe
the DTC pioneer whose opt-in DNA database passed 15 million profiles and funded a drug-discovery arm; after a voluntary Chapter 11 process in March 2025 and a court-supervised sale, it continues ordinary operations under restructured ownership,…
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| DTC genetic testing | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.